Member Info for MaryBr190

Looking like institutions are buying biggly too. Backwardation atm.

Whilst not without risks this was a screaming buy sub 177p today so topped up biggl. Heading all the way back through £2 just now.

If you need to bandy figures around at least report what was known.

Underlying profit before tax is now expected to be in the range of £90-100 million, down from £110-120 million guidance in July and £115-125 million in May.

Readded the 176 sales

Should be starting with a £4 not a £2 or a £3 - let's roll.

Poolbeg Pharma is experiencing significant momentum due to its advancements in drug development, particularly in oncology and metabolic diseases. The company is focused on innovative treatments that address unmet medical needs, which has garnered attention from investors and analysts alike.

Key Developments

• Pipeline Advancements: Poolbeg's lead asset, POLB 001, is designed to target cytokine release syndrome (CRS), a serious condition affecting many cancer patients undergoing immunotherapy. This oral therapy could potentially transform treatment options, as there are currently few effective preventative measures for CRS.

• Funding and Partnerships: The company recently raised at least £4 million to accelerate its key programs, including POLB 001 and an oral GLP-1 receptor agonist project aimed at obesity treatment. This funding is crucial for advancing clinical trials and attracting commercial partners.

• Upcoming Trials: The Phase 2a trial for POLB 001 is expected to begin soon, with interim results anticipated in the first half of 2026. The involvement of major pharmaceutical companies in supplying key biologics for the trial indicates strong confidence in Poolbeg's strategy.

• Innovative Approaches: Poolbeg is also exploring an oral encapsulated formulation of GLP-1, which aims to improve the bioavailability of peptide-based therapies. This project is set to enter a proof-of-concept trial later this year.

• AI-Driven Drug Discovery: Beyond its primary programs, Poolbeg is leveraging AI for drug discovery, focusing on significant health threats like influenza and RSV, which reflects its broader ambition to utilize data-driven science for impactful solutions.

Overall, Poolbeg Pharma is at a pivotal point, with its lead programs advancing into human trials and a strong pipeline that could lead to transformative treatments in the near future.

Momentum, director buying, potential bagger. Finance sorted, updates due. Great mix for a harrier move up.

Good call Carrington - wished I had trimmed more but an easy path (bounce) to 30p over the next period could see follow through. It all seems deja vu of the last time we were sub 25p and that was an opportunity. Bargain for a bid and perhaps that was the intention for Cosmens.

Getting interesting to add back the near 40p trims so snatched a few for a trade

Analyst Updates

• MarketBeat: Analysts have indicated a consensus price target of 19 GBX for Poolbeg Pharma, suggesting a potential upside of 381.01% from current levels. This target reflects optimism about the company's growth prospects and ongoing clinical developments.

• Investing.com: According to their analysis, the average 12-month price target for Poolbeg Pharma is also set at 19 GBX, with a high estimate of 19 GBX. This reinforces the bullish sentiment among analysts regarding the company's future performance.

• Stockscan: They project a more aggressive forecast, estimating that Poolbeg Pharma could reach an average price of 0.6497 USD in the next 30 days, representing a 1,429% increase from its current price. The highest target from this analysis is 0.6988 USD, while the lowest is 0.6006 USD.

You missed the :) like many things.

Sidara faffing around making WG. BoD look competent :).

Land this afternoon.

https://media1.tenor.com/m/o9jjRbS4D0oAAAAC/boat.gif

Up up and away. Great to see.

37 to 151 to 60 to 100 plenty of fun to be had. 72p again a small nibble perhaps in anticipation of another spike.

OT WPP well oversold. Quality now building from the lows.

@LWHL

Add at sub 60, sub 50 sub 40 if it gets there and lighten up the rises.Just do not go all in and hold until it turns. Add trim to win. On your bike with a spike! AC tumbles.

Sentiment, budget woes, sin tax, labour trashing th economy and fleecing middle classes. Buy the dip. DYOR.

Back to readding. ISA gift that keeps on giving.

Way oversold but having picked up the dividend cautiously trimming . Expecting this to have been the bottom and looking at 440-460 as the next leg on the way to full recovery.